Skip to main content
SkinCited

Hyperpigmentation
Hyperpigmentation

Prevalensi: Melasma affects 15-50% of pregnant women; PIH common in darker skin tones (Fitzpatrick IV-VI)

<\/script>\n
`; }, get iframeSnippet() { const domain = 'skincited.com'; const params = 'condition\u003Dhyperpigmentation'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Evidence-Ranked Ingredients

About

{# Filter order is load-bearing: escape (untrusted text) -> linebreaks (paragraphs) -> paper anchors (internal /papers/ links) -> glossary (never links inside an existing ). #}

Three distinct processes produce the darkened patches grouped under hyperpigmentation, and they respond differently. Melasma is hormonally driven and affects 15 to 50 percent of pregnant women, appearing symmetrically on the cheeks, forehead and upper lip. Post-inflammatory hyperpigmentation follows acne or injury and is common in Fitzpatrick skin types IV to VI. Solar lentigines accumulate with cumulative sun exposure. All three end in the same place, excess melanin deposited in the epidermis or dermis, but they begin at different triggers. Five ingredients carry an evidence grade here, all of them Grade C, across 19 studies and about 1,070 participants.

The shared endpoint is tyrosinase, the rate-limiting enzyme of melanin synthesis, together with the transfer of finished melanosomes from melanocytes into surrounding keratinocytes. Ultraviolet light, inflammatory mediators and estrogen signalling each upregulate that pathway. Where the pigment lands determines how stubborn it is: epidermal deposition turns over with the keratinocyte cycle, while dermal deposition sits below the basement membrane and persists far longer.

Glutathione carries the widest base in this set at 6 studies and 350 participants. Its proposed action is a shift in melanogenesis from darker eumelanin toward lighter pheomelanin, along with direct inhibition of tyrosinase. Oral bioavailability is the recurring objection, since glutathione is a tripeptide subject to intestinal hydrolysis, and trials have used varying forms and doses that complicate pooling.

Pine bark extract, or pycnogenol, is supported by 4 studies and 240 participants, and Polypodium leucotomos, grape seed extract and N-acetyl cysteine each rest on 3 studies with 150 to 240 participants. The mechanistic thread running through them is antioxidant rather than direct enzymatic: by reducing ultraviolet-induced reactive oxygen species and the inflammatory signalling that follows, they act upstream of pigment production rather than on the melanocyte itself. That is consistent with the observation that the same compounds appear in the internal photoprotection literature.

A uniform Grade C across every entry is the most important fact on this page. It reflects small samples, short durations and a scarcity of the objective colorimetric measurement that would allow results to be compared between studies. Sun exposure is also the dominant variable in all three subtypes, so any trial that does not standardise ultraviolet exposure is measuring photoprotection and supplementation together.

The practical implication is one of sequence rather than substitution. Broad-spectrum sun protection is the intervention with the strongest support for every subtype, and the graded ingredients here are studied as additions to it. Melasma in particular tends to recur when the hormonal or ultraviolet trigger returns, and dermal pigment resists oral approaches. Persistent or rapidly changing pigmented lesions require clinical evaluation, since a change in an existing spot is also how several serious dermatologic conditions present.

Common Symptoms

Dark patches on face (melasma: cheeks, forehead, upper lip) Dark spots at sites of prior acne or injury (PIH) Age spots (solar lentigines) Uneven skin tone

Risk Factors

  • Sun exposure
  • Hormonal changes (pregnancy, oral contraceptives)
  • Skin inflammation or injury
  • Darker skin tones
  • Family history
  • Certain medications

Frequently Asked Questions

What supplements are studied for Hyperpigmentation?
Research has examined 5 supplement ingredients for Hyperpigmentation, including Glutathione. Evidence strength varies; review individual grades for details.
How is the evidence for Hyperpigmentation supplements graded?
We grade supplements on an A-F scale based on clinical study quality, consistency of results, sample sizes, and study design. Grade A indicates strong evidence from multiple clinical trials, while Grade D indicates preliminary evidence requiring further research.
How many studies on Hyperpigmentation supplements have been reviewed?
Our evidence grades for Hyperpigmentation are based on a total of 19 peer-reviewed studies across 5 ingredients. Studies are sourced from PubMed and include randomized controlled trials, meta-analyses, and other clinical research.
What are common symptoms of Hyperpigmentation?
Common symptoms associated with Hyperpigmentation include Dark patches on face (melasma: cheeks, forehead, upper lip), Dark spots at sites of prior acne or injury (PIH), Age spots (solar lentigines), Uneven skin tone. If you are experiencing these symptoms, consult a healthcare professional for proper diagnosis and treatment options.

Kondisi yang berbagi bahan yang telah diteliti

Penafian FDA: Pernyataan-pernyataan ini belum dievaluasi oleh Food and Drug Administration. Produk dan informasi di situs web ini tidak dimaksudkan untuk mendiagnosis, mengobati, menyembuhkan, atau mencegah penyakit apa pun. Peringkat bukti yang disajikan didasarkan pada analisis kami terhadap penelitian yang ditinjau sejawat dan tidak merupakan saran medis. Selalu konsultasikan dengan penyedia layanan kesehatan Anda sebelum memulai regimen suplemen apa pun.